2024
County-level racial disparities in prostate cancer specific mortality from 2005 to 2020
Washington S, Fakunle M, Wang L, Braun A, Leapman M, Cowan J, Cooperberg M. County-level racial disparities in prostate cancer specific mortality from 2005 to 2020. JNCI Cancer Spectrum 2024, pkae109. PMID: 39495143, DOI: 10.1093/jncics/pkae109.Peer-Reviewed Original ResearchNon-Hispanic blacksRacial disparitiesCancer-specific mortalityCancer outcomesAssociated with lower mortality riskProstate cancer-specific mortalityProstate cancer outcomesNon-Hispanic white patientsLinear mixed models evaluated associationsPrimary care providersSpecific mortalityRadiation oncologist densityLower mortality riskYear of deathBlack-white differencesRace-based disparitiesMortality disparitiesProvider densityCare providersCounty-level dataHospital bedsMortality riskData of menProstate cancer specific mortality riskWhite patients
2023
Prostate cancer disparities among American Indians and Alaskan Natives in the United States
Chu C, Leapman M, Zhao S, Cowan J, Washington S, Cooperberg M. Prostate cancer disparities among American Indians and Alaskan Natives in the United States. Journal Of The National Cancer Institute 2023, 115: 413-420. PMID: 36629492, PMCID: PMC10086629, DOI: 10.1093/jnci/djad002.Peer-Reviewed Original ResearchConceptsProstate cancer-specific mortalityProstate-specific antigenAlaska Native patientsCancer-specific mortalityGleason scoreNative patientsDefinitive treatmentWhite patientsProstate cancerTreatment accessAlaska NativesProvider densityHigher prostate-specific antigenAdvanced prostate cancerPatterns of careExternal beam radiationAmerican IndiansProstate cancer disparitiesCounty-level demographicsHealth policy interventionsLower ratesMultivariable adjustmentBaseline characteristicsPathologic factorsWorse survivalProstate cancer risk, screening and management in patients with germline BRCA1/2 mutations
Rajwa P, Quhal F, Pradere B, Gandaglia G, Ploussard G, Leapman M, Gore J, Paradysz A, Tilki D, Merseburger A, Morgan T, Briganti A, Palapattu G, Shariat S. Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations. Nature Reviews Urology 2023, 20: 205-216. PMID: 36600087, DOI: 10.1038/s41585-022-00680-4.Peer-Reviewed Original ResearchConceptsProstate cancer riskBRCA1/2 mutation carriersMagnetic resonance imagingProstate cancerMutation carriersCancer riskProspective studyBRCA2 mutationsProstate cancer-specific mortalityProstate specific antigen measurementsCancer-specific mortalityProstate cancer incidenceAggressive clinical behaviorProstate cancer screeningRisk stratification strategiesLong-term resultsSignificant prostate cancerOptimal screening strategyGermline BRCA1/2 mutationsOptimal screening protocolProstate magnetic resonance imagingQuality of lifeBRCA2 tumor suppressor genesOverall survivalDisease characteristics
2016
External validation of a prognostic Gleason grade classification system.
Leapman M, Cowan J, Roberge G, Eltemamy M, Simko J, Carroll P, Cooperberg M. External validation of a prognostic Gleason grade classification system. Journal Of Clinical Oncology 2016, 34: 123-123. DOI: 10.1200/jco.2016.34.2_suppl.123.Peer-Reviewed Original ResearchProstate cancer-specific mortalityRisk of recurrenceGleason grade groupRadical prostatectomyAdjusted pairwise comparisonsGrade groupUCSF cohortGrade diseaseGleason 4Metastatic progressionCox proportional hazards modelGleason classification systemGrade classification systemImmediate radical prostatectomyCancer-specific mortalityAcademic referral centerHigh-grade diseaseIndependent prognostic abilityProportional hazards modelConsecutive PSA valuesDiscrimination of outcomesGleason grading systemGleason grade 3Salvage treatmentReferral center